Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics, Inc. (PVLA)
:PVLA
RESEARCH TOOLSreports
PVLA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.20 - $22.32
Previous CloseN/A
Volume11.83K
Average Volume (3M)49.91K
Market Cap
$235.54M
Enterprise Value-$954.53K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.54
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.61
Shares Outstanding11,221,307
10 Day Avg. Volume64,090
30 Day Avg. Volume49,909
Standard Deviation0.25
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)32.04
Price to Cash Flow (P/CF)47.50
P/FCF Ratio47.50
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.95
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$37.75Price Target Upside80.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Financial PositionPalvella is well positioned for both short-term and long-term goals, with approximately $80M in cash and cash equivalents expected to fund operations into the second half of 2027.
Market PotentialQTORIN rapamycin could become the first approved therapy and first-line treatment option for microcystic lymphatic malformations if Phase 3 results are positive.
Regulatory DesignationsThe Phase 3 SELVA trial has been granted Breakthrough Designation, Fast Track Designation, and Orphan Drug Designation by the FDA.
Bears Say
Market CompetitionThe cutaneous VM market presents a significantly larger opportunity compared to microcystic lymphatic malformations.
Market UncertaintyThe true size of the cutaneous VM market is questioned due to the lack of an ICD9 code for cutaneous specific disease.
Treatment Efficacy ChallengesThe ability of QTORIN rapamycin to achieve success in treating cutaneous venous malformations (VMs) is essential for Palvella to reach its peak sales potential.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.52% Insiders
0.16% Mutual Funds
29.15% Other Institutional Investors
67.06% Public Companies and Individual Investors
PVLA FAQ
What was Palvella Therapeutics, Inc.’s price range in the past 12 months?
Palvella Therapeutics, Inc. lowest stock price was $6.20 and its highest was $22.32 in the past 12 months.
What is Palvella Therapeutics, Inc.’s market cap?
Palvella Therapeutics, Inc.’s market cap is $235.54M.
When is Palvella Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Palvella Therapeutics, Inc.’s earnings last quarter?
Palvella Therapeutics, Inc. released its earnings results on Mar 27, 2024. The company reported -$3.706 earnings per share for the quarter, beating the consensus estimate of -$9.6 by $5.894.
Is Palvella Therapeutics, Inc. overvalued?
According to Wall Street analysts Palvella Therapeutics, Inc.’s price is currently Undervalued.
Does Palvella Therapeutics, Inc. pay dividends?
Palvella Therapeutics, Inc. does not currently pay dividends.
What is Palvella Therapeutics, Inc.’s EPS estimate?
Palvella Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palvella Therapeutics, Inc. have?
Palvella Therapeutics, Inc. has 11,221,307 shares outstanding.
What happened to Palvella Therapeutics, Inc.’s price movement after its last earnings report?
Palvella Therapeutics, Inc. reported an EPS of -$3.706 in its last earnings report, beating expectations of -$9.6. Following the earnings report the stock price went up 0.906%.
Which hedge fund is a major shareholder of Palvella Therapeutics, Inc.?
Currently, no hedge funds are holding shares in PVLA
---
Palvella Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.75 (80.02% Upside)
$37.75 (80.02% Upside)
Hedge Fund Trend
Decreased
By 12.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $51.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 4.7%
Last 30 Days ▼ 11.3%
Last 30 Days ▼ 11.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.81%
12-Months-Change
Fundamentals
Return on Equity
-68.21%
Trailing 12-Months
Asset Growth
-65.44%
Trailing 12-Months
Company Description
Palvella Therapeutics, Inc.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
---
PVLA Stock 12 Month Forecast
Average Price Target
$37.75
▲(80.02% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
SAGE Therapeutics
―
Best Analysts Covering PVLA
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+31.80%
initiated a buy rating 2 months ago
Copying Joshua Schimmer's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.80% per trade.
---